Spots Global Cancer Trial Database for computed tomography with contrast

Every month we try and update this database with for computed tomography with contrast cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study	NCT04430725	Lung Non-Small ... Metastatic Colo... Metastatic Sarc... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color...	Computed Tomogr... Microwave Ablat... Questionnaire A... Wedge Excision	18 Years -	M.D. Anderson Cancer Center
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	NCT03191149	Advanced Lung N... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung N...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Osimertinib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer	NCT04394858	Advanced Adrena... Advanced Paraga... Metastatic Adre... Metastatic Para... Stage III Adren... Stage IV Adrena... Unresectable Ad... Unresectable Pa...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Quality-of-Life... Temozolomide	18 Years -	National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	NCT03237780	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla...	18 Years -	National Cancer Institute (NCI)
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	NCT04739800	Fallopian Tube ... Ovarian Seromuc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Low ... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim...	Biospecimen Col... Cediranib Malea... Computed Tomogr... Computed Tomogr... Durvalumab Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer	NCT03237780	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Eribulin Mesyla...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer	NCT04394858	Advanced Adrena... Advanced Paraga... Metastatic Adre... Metastatic Para... Stage III Adren... Stage IV Adrena... Unresectable Ad... Unresectable Pa...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Quality-of-Life... Temozolomide	18 Years -	National Cancer Institute (NCI)
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study	NCT04430725	Lung Non-Small ... Metastatic Colo... Metastatic Sarc... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage II Lung C... Stage IIA Lung ... Stage IIB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color...	Computed Tomogr... Microwave Ablat... Questionnaire A... Wedge Excision	18 Years -	M.D. Anderson Cancer Center
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer	NCT04981509	Hereditary Leio... Papillary Renal... Renal Cell Carc... Sporadic Papill... Stage III Renal... Stage IV Renal ...	Atezolizumab Bevacizumab Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Computed Tomogr... Erlotinib Magnetic Resona... Positron Emissi... Sodium Fluoride...	12 Years -	National Cancer Institute (NCI)
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	NCT03191149	Advanced Lung N... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung N...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Osimertinib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: